000280975 001__ 280975
000280975 005__ 20250918102645.0
000280975 0247_ $$2doi$$a10.1007/s40120-025-00778-y
000280975 0247_ $$2pmid$$apmid:40504345
000280975 0247_ $$2pmc$$apmc:PMC12255591
000280975 0247_ $$2ISSN$$a2193-6536
000280975 0247_ $$2ISSN$$a2193-8253
000280975 037__ $$aDZNE-2025-01057
000280975 041__ $$aEnglish
000280975 082__ $$a610
000280975 1001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b0$$eFirst author
000280975 245__ $$aDifferentiation Between Early and Severe Stages of Dementia in Claims Data Based on Diagnosis, Prescription, and Utilization Patterns.
000280975 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2025
000280975 3367_ $$2DRIVER$$aarticle
000280975 3367_ $$2DataCite$$aOutput Types/Journal article
000280975 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756891649_1280
000280975 3367_ $$2BibTeX$$aARTICLE
000280975 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280975 3367_ $$00$$2EndNote$$aJournal Article
000280975 520__ $$aClaims data typically lack clinical parameters such as dementia severity, limiting insights into disease progression and related healthcare utilization and costs. Although diagnoses, prescriptions, and utilization patterns may serve as proxies, their validity is unclear. This study aimed to identify and validate these parameters to distinguish early from severe dementia stages.Baseline data from 737 patients with dementia were analyzed. Dementia severity was assessed using the Mini-Mental State Examination and classified as early (≥ 27), mild (20-26), and moderate to severe (0-19). Healthcare utilization was recorded via structured interviews. Diagnoses, long-term care levels, and prescribed medications were extracted from physicians' files. Ordinal logistic regression evaluated associations between predictors and severity, with average marginal effects (AME) quantifying impact. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed for key predictors.Among the sample (56% female patients, mean age 80), 18% were in the early stages, 43% mild, and 39% moderate to severe. Antipsychotic prescriptions (odds ratio (OR) 3.40, 95% confidence interval (CI) 1.94-5.95), antidementia drugs (OR 2.31, 95% CI 1.56-3.40), and higher long-term care levels (OR 5.59, 95% CI 2.23-13.99 for level ≥ 4) were associated with advanced severity. AME analysis revealed that antipsychotic use reduced early-stage probability by 14% and increased severe-stage probability by 21%. Similarly, antidementia drugs lowered early-stage probability by 9% and raised severe-stage probability by 13%. Increasing care levels were associated with a 2-16% decline in early-stage probability and a 3-34% rise in severe-stage probability. The combined model showed high specificity (99.6%) and PPV (84.6%) for severe dementia, but sensitivity and NPV for early stage were low.Antidementia drugs, antipsychotics, and long-term care level serve as robust predictors of moderate to severe dementia, whereas early-stage detection remains challenging. Future studies should validate these markers and explore additional predictors to improve early detection in claims data.
000280975 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280975 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280975 650_7 $$2Other$$aAlzheimer’s disease
000280975 650_7 $$2Other$$aAntidementia drug treatment
000280975 650_7 $$2Other$$aAntipsychotics
000280975 650_7 $$2Other$$aClaims data
000280975 650_7 $$2Other$$aDementia
000280975 650_7 $$2Other$$aDementia severity
000280975 650_7 $$2Other$$aHealthcare utilization
000280975 650_7 $$2Other$$aReal-world data
000280975 650_7 $$2Other$$aReal-world evidence
000280975 7001_ $$0P:(DE-2719)9002138$$aBuchholz, Maresa$$b1$$udzne
000280975 7001_ $$0P:(DE-2719)9001134$$aRädke, Anika$$b2$$udzne
000280975 7001_ $$0P:(DE-2719)9003305$$aGlaeser, Eva$$b3$$udzne
000280975 7001_ $$0P:(DE-2719)9003158$$aIskandar, Audrey$$b4$$udzne
000280975 7001_ $$0P:(DE-HGF)0$$avan den Berg, Neeltje$$b5
000280975 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b6$$udzne
000280975 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b7$$eLast author$$udzne
000280975 773__ $$0PERI:(DE-600)2682228-3$$a10.1007/s40120-025-00778-y$$gVol. 14, no. 4, p. 1589 - 1608$$n4$$p1589 - 1608$$tNeurology and Therapy$$v14$$x2193-6536$$y2025
000280975 8564_ $$uhttps://pub.dzne.de/record/280975/files/DZNE-2025-01057.pdf$$yOpenAccess
000280975 8564_ $$uhttps://pub.dzne.de/record/280975/files/DZNE-2025-01057%20SUP.pdf
000280975 8564_ $$uhttps://pub.dzne.de/record/280975/files/DZNE-2025-01057%20SUP.pdf?subformat=pdfa$$xpdfa
000280975 8564_ $$uhttps://pub.dzne.de/record/280975/files/DZNE-2025-01057.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280975 909CO $$ooai:pub.dzne.de:280975$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003305$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003158$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000280975 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000280975 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280975 9141_ $$y2025
000280975 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL THER : 2022$$d2024-12-18
000280975 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000280975 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:42:53Z
000280975 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:42:53Z
000280975 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280975 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000280975 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000280975 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x0
000280975 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x1
000280975 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x2
000280975 980__ $$ajournal
000280975 980__ $$aVDB
000280975 980__ $$aUNRESTRICTED
000280975 980__ $$aI:(DE-2719)5000067
000280975 980__ $$aI:(DE-2719)1510600
000280975 980__ $$aI:(DE-2719)1510800
000280975 9801_ $$aFullTexts